| abstract |
Described herein is to determine if a subject with cancer (s) is likely to respond to treatment with an HSP90 inhibitor as a single agent or in combination therapy Compositions, kits, and methods for Further described is a method for predicting the time course of disease in a subject having such cancer. For example, a method is provided for determining responsiveness to a treatment comprising an HSP90 inhibitor in a tumor or cancer cell, or a subject having or at risk of having the tumor or cancer cell. |